Fostamatinib in Chronic ITP

Fostamatinib in Chronic ITP

Current Status
Not Enrolled
Get Started

Author: Dr. Farid Azadian, University of Ottawa

Reviewer: Dr. Siraj Mithoowani, Assistant Professor, Dept of Medicine, McMaster University


At the end of the self-assessment module, participants will be able to:

  1. Describe first and second-line therapies for immune thrombocytopenia
  2. Describe the mechanism of action and clinical efficacy of fostamatinib
  3. Explain the safety profile and routine monitoring for fostamatinib therapy

CHS Scientific Planning Committee Members (2022-23)

Dr. Joanne Britto – Clinical Fellow – Malignant Hematology, McMaster University
Dr. Danyal Ladha – Resident
Dr. Yan Xu – Fellow Physician, Hematology
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflicts of Interest: None